“…Furthermore, the diversity of proteasomes can be increased by hundreds of proteasome-interacting proteins including the Ecm29 protein, the deubiquitinating enzymes Usp14, and Uch37, which have all either studied as or could become novel therapeutic targets (Figure 4) (267, 288, 295–298). For example, Usp14 overexpression was observed in lung, breast, pancreatic, gastric, and endometrial cancer (289, 295, 299) and its inhibition via RNA interference or small molecule inhibitors resulted in reduced proliferation invasion and increased apoptosis in lung, breast, pancreatic, prostate, endometrial cancer, and melanoma cells (288, 289, 295, 296). The downregulation of Usp14 ensured smaller tumor sizes and longer survival in nude mice injected with lung cancer or melanoma cells (288, 289).…”